Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Subscribe To Our Newsletter & Stay Updated
